Optimization of Small Molecule Probes for the Nervous System (R21)

The summary for the Optimization of Small Molecule Probes for the Nervous System (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Optimization of Small Molecule Probes for the Nervous System (R21): Purpose. The aim of this FOA issued by the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute on Drug Abuse (NIDA) is to facilitate the discovery of new small molecule probes for investigating biological function in the nervous system by providing funding for advanced medicinal chemistry and the biological testing of compounds. Eligible Investigators will have identified probe candidates via screening of small molecule collections, using in vitro assays of biological activity developed to interrogate these collections, and be able to show that the structural features of these small molecules are related to their biological activity. Project proposals should nominate small molecule probe candidates from distinct structural series for the further, iterative design and testing of analogues in structure-activity relationship studies, using in vitro assays of biological function adapted to the medium throughput screening requirements of this work. These studies should have the goal of developing a small molecule probe possessing the attributes (eg: affinity, selectivity, activity) required for its use in future pharmacological studies proposed by the investigator. Applicants are strongly encouraged to utilize publicly available cheminformatic capabilities for the acquisition of compounds, and semi-custom synthesis of analogues, which is required of these studies.